In conclusion, there is no doubt that syntenin is the protein reactive with cancer and control sera in spot 41.
There are, however, many other peptides that are vaccine candidates having the ability to induce HLA-class-I-restricted CTLs reactive to cancer cells.
Spot 41, identified as syntenin, was another candidate differentially reactive with cancer versus control sera (8/21 versus 5/24 respectively), although this difference did not reach significance when a Fisher exact test was performed (table 3).
Thus, T cells moving through solid tumors in blood vessels are not reactive to cancer-associated antigens.
Determining the NK cell subsets that are tumor-reactive in cancer patients remains a challenge.
*Adjusted for age, gender, race, smoking, income, log c-reactive protein, cancer, eGFR log albumin-creatinine ratio and sodium intake.
In nude mice bearing xenografts of the MAb A7-reactive gastric cancer line MKN45, the percentage injected dose of MAb A7 per g of tumour tissue on day 7 was 9.79; this value was 77% of that on day 1.
When adjusting for age, gender, race, smoking, house-hold income, c-reactive protein, cancer, eGFR, albumin/creatinine ratio, and sodium intake, an increase in BMI, WC, or percent body fat were not significantly associated with mortality Figure 2).
Cox proportional hazards analyses were used to assess the association between different body measurements (BMI, WC, percent fat and lean body mass) and mortality while adjusting for age, gender, race, smoking status, income, salt intake, log c-reactive protein, cancer, eGFR and log albumin/creatinine ratio.
In the 'hypothesis-free', purely statistical analysis (GBM method), C-reactive protein, cancer antigen 72-4, cellularlular fibronectin, insulin-like growth factor binding protein 1, ICAM-1, IL-6, IL-8, IL-18, mannose receptor C type 2, MMP7, tenascin C and TIMP metallopeptidase inhibitor 1 were identified as prognostic factors.
